Editorial on the relationship between suPAR and CKD, published in NEJM

Wed Oct 21 2020

“A suPAR Biomarker for Chronic Kidney Disease”, published in the New England Journal of Medicine

Chronic Kidney Disease (CKD) is a global epidemic and often a death sentence in areas without access to renal-replacement therapies. Detecting CKD early is crucial, but current methods only identify decreased renal function after significant damage. There is a critical need for new biomarkers to accurately assess the risk of CKD while kidney function remains good, increasing the chance that treatments can slow or stop its progression.

Studies proving that interventions based on suPAR levels are effective could establish a strong link between suPAR and CKD.

1000+

published suPAR studies in leading medical journals

Nature Medicine Logo
Science Journal Logo
JAMA Pediatrics Logo

The suPARnostic® brand consists of four products:

Quick Triage
TurbiLatex
ELISA
POC+

Quick Triage

A Point of Care Solution

TurbiLatex

For Automated Systems

ELISA Assay

Clinical and Research

POC+

Point-of-care finger prick

New Webinar

Webinar

Catch COVID-19

-Improve your triage

Sign up to view webinar recording

View recording

suPARnostic® by ViroGates